title: Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique.
abstract: We evaluated the impact of intermittent preventive treatment in infants (IPTi) with sulfadoxine-pyrimethamine (SP), which was given at ages 3, 4, and 9 months through the Expanded Program on Immunization (EPI), on the development of antibody responses to Plasmodium falciparum in Mozambique. Immunoglobulin M (IgM) and IgG subclass antibodies specific to whole asexual parasites and to recombinant MSP-1(19), AMA-1, and EBA-175 were measured at ages 5, 9, 12, and 24 months for 302 children by immunofluorescence antibody tests and by enzyme-linked immunosorbent assays. Antibody responses did not significantly differ between children receiving IPTi with SP and those receiving a placebo at any time point measured, with the exception of the responses of IgG and IgG1 to AMA-1 and/or MSP-1(19), which were significantly higher in the SP-treated group than in the placebo group at ages 5, 9, and/or 24 months. IPTi with SP given through the EPI reduces the frequency of malarial illness while allowing the development of naturally acquired antibody responses to P. falciparum antigens.
authors.affiliation: Centro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
authors.forename: Diana
authors.initials: D
authors.lastname: Quelhas
authors.forename: Laura
authors.initials: L
authors.lastname: Puyol
authors.forename: Llorenç
authors.initials: L
authors.lastname: Quintó
authors.forename: Elisa
authors.initials: E
authors.lastname: Serra-Casas
authors.forename: Tacilta
authors.initials: T
authors.lastname: Nhampossa
authors.forename: Eusebio
authors.initials: E
authors.lastname: Macete
authors.forename: Pedro
authors.initials: P
authors.lastname: Aide
authors.forename: Alfredo
authors.initials: A
authors.lastname: Mayor
authors.forename: Inacio
authors.initials: I
authors.lastname: Mandomando
authors.forename: Sergi
authors.initials: S
authors.lastname: Sanz
authors.forename: John J
authors.initials: JJ
authors.lastname: Aponte
authors.forename: Virander S
authors.initials: VS
authors.lastname: Chauhan
authors.forename: Chetan E
authors.initials: CE
authors.lastname: Chitnis
authors.forename: Pedro L
authors.initials: PL
authors.lastname: Alonso
authors.forename: Clara
authors.initials: C
authors.lastname: Menéndez
authors.forename: Carlota
authors.initials: C
authors.lastname: Dobaño
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use; D002675:Child, Preschool; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004912:Erythrocytes / Q000469:parasitology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007223:Infant; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control*; D009073:Mozambique; D010963:Plasmodium falciparum / Q000276:immunology*; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D013413:Sulfadoxine / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000962:Antimalarials; D004338:Drug Combinations; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011994:Recombinant Proteins; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine